Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Krensavage Asset Management, LLC

Q2 2023 · 13F-HR

Krensavage Asset Management, LLCholdings as filed

Filed 2023-08-11 · accession 0001609251-23-000004

$315,622
Reported value
12
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
09062X103BIIBBIOGEN INC$50,36916.0%176,826CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$44,74914.2%202,715CommonSOLE
75886F107REGNREGENERON PHARMACEUTICALS$42,52913.5%59,188CommonSOLE
30161Q104EXELEXELIXIS INC$40,77512.9%2,133,703CommonSOLE
G01767105ALKSALKERMES PLC$34,53810.9%1,103,451CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$33,45110.6%353,714CommonSOLE
M8737E108TARO PHARMACEUTICAL INDUS$24,3927.73%643,080CommonSOLE
29082K105EMBCEMBECTA CORP$23,1297.33%1,070,810CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$14,7154.66%687,613CommonSOLE
921659108VNDAVANDA PHARMACEUTICALS INC$2,3920.76%362,951CommonSOLE
50015M109KODKODIAK SCIENCES INC$2,3780.75%344,634CommonSOLE
269796108EGRXEAGLE PHARMACEUTICALS INC$2,2050.70%113,437CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.